Zika no threat to plasma-derived drugs, says EU regulator
[LONDON] Patients who take medicines derived from blood plasma or urine are not at increased risk of catching Zika, even if the body fluids come from countries where the virus is prevalent, Europe's drugs regulator said on Wednesday.
Plasma-derived products are used to treat some serious blood conditions and to help fight infections, while urine-based medicines include certain hormone treatments and therapies to help break up blood clots.
The European Medicines Agency, Europe's equivalent of the US Food and Drug Administration (FDA), said its experts had assessed the risks and concluded that manufacturing processes used for such products would inactivate or remove the Zika virus.
This includes the use of solvents or detergents, pasteurisation and filtration.
Health authorities are currently taking extra care with whole blood donations. Last month, the FDA recommended that all blood donations be tested for Zika in a drive to prevent transmission of the virus through the blood supply.
REUTERS
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
International
South Korea’s economic growth beats forecast as exports rise
China 2024 growth outlook raised to 4.8%, deflation risk lingers
Luxury sector outlook clouded by China’s slow recovery
‘We aren’t going anywhere’: TikTok CEO expects to defeat US restrictions
TikTok artists and advertisers to stay with app until ‘door slams shut’
Biden signs Ukraine aid, TikTok ban Bills after Republican battle